Cardiology

Wool heart
Favicon Fierce Biotech

Don't count out Alnylam's next-gen silencer in ATTR-CM: analysts

Patients' disease stage, transthyretin knockdown levels and trial design have become focal points in debates around silencer-stabilizer combos.